{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:07:47Z","timestamp":1790143667965,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.yexmp.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T03:31:42Z","timestamp":1484191902000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt"],"prefix":"10.1016","volume":"102","author":[{"given":"Amira B.","family":"Kassem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem Eid","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira S.A.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-4284","authenticated-orcid":false,"given":"Ahmad","family":"Salahuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Mahmoud","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer A.","family":"Bahnassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2017.01.006_bb0005","first-page":"1171","article-title":"Colorectal cancer below thirty in Alexandria University hospitals","volume":"12","author":"Abou-El Eneine","year":"1986","journal-title":"Bull. Alex. Fac. Med."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2125.1999.00010.x","article-title":"A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer","volume":"48","author":"Adjei","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0959-8049(02)00411-2","article-title":"Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines","volume":"39","author":"Arnould","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1369\/jhc.3A6195.2004","article-title":"Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues variation in staining intensity due to choice of fixative and storage time of tissue sections","volume":"52","author":"Atkins","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/bjc.2012.526","article-title":"KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients","volume":"108","author":"Basso","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0030","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1586\/14737140.8.8.1223","article-title":"Oxaliplatin-based chemotherapy in the management of colorectal cancer","volume":"8","author":"Capdevila","year":"2008","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0035","article-title":"ERCC1 and TS expression as prognostic and predictive biomarkers in metastatic colon cancer","volume":"10","author":"Choueiri","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/or.2011.1133","article-title":"ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation","volume":"25","author":"De Castro Jr","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0045","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0050","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2010.08.019","article-title":"Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone","volume":"97","author":"Doll","year":"2010","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0060","series-title":"Topographic Pathology of Cancer","first-page":"63","author":"El-Bolkainy","year":"1998"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0065","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1002\/cncr.25417","article-title":"The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer","volume":"116","author":"El-Serafi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0070","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/3327","article-title":"Real-time quantitative RT\u2013PCR after laser-assisted cell picking","volume":"4","author":"Fink","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/tpj.2011.29","article-title":"TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials","volume":"12","author":"Grimminger","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0080","first-page":"1111","article-title":"Correlation of ERCCl, BRCAl expression and chemotherapeutic effect and prognosis of oxaliplatin regimens in advanced colon cancer tissues","volume":"41","author":"Gu","year":"2014","journal-title":"Cancer Res. Prev. Treat."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0085","first-page":"225","article-title":"Colorectal cancer in young patients: a review of the literature","volume":"20","author":"Heys","year":"1994","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jso.23422","article-title":"Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy","volume":"108","author":"Huang","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e31817be58e","article-title":"Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase \u03c0 for 5-FU\/oxaliplatin chemotherapy in advanced colorectal cancer","volume":"32","author":"Kim","year":"2009","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0100","series-title":"ASCO Annual Meeting Proceedings","first-page":"493","article-title":"MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"vol. 34","author":"Lenz","year":"2016"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0105","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/bjc.2013.83","article-title":"ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy","volume":"108","author":"Li","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jcla.20494","article-title":"ERCC1 and XPD\/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis","volume":"26","author":"Lu","year":"2012","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0115","article-title":"Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis","volume":"8","author":"Ma","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF02234737","article-title":"Colorectal adenocarcinoma in patients under 45years of age: comparison with older patients in a well-defined French population","volume":"44","author":"Mitry","year":"2001","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0135","first-page":"8654","article-title":"A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0140","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Shirota","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1097-0215(19970328)71:1<26::AID-IJC6>3.0.CO;2-5","article-title":"Colorectal cancer in Egyptian patients under 40years of age","volume":"71","author":"Soliman","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0155","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/365852a0","article-title":"Human xeroderma pigmentosum group D gene encodes a DNA helicase","volume":"365","author":"Sung","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0160","first-page":"176","article-title":"CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"vol. 13","author":"Trotti","year":"2003"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0165","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-8-386","article-title":"Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine","volume":"8","author":"Uchida","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0921-8777(00)00051-3","article-title":"DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes","volume":"461","author":"Vogel","year":"2000","journal-title":"Mutat. Res.\/DNA Repair"},{"key":"10.1016\/j.yexmp.2017.01.006_bb0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/em.1073","article-title":"ERCC1: a comparative genomic perspective","volume":"38","author":"Wilson","year":"2001","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yexmp.2017.01.006_bb0180","first-page":"009","article-title":"ERCC1 and BRCA1 expressions in the tissues of colorectal cancer and its relationship with clinical significance of platinum-based chemotherapy [J]","volume":"4","author":"Xu","year":"2011","journal-title":"Fudan Univ. J. Med. Sci."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480016303112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480016303112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:21:53Z","timestamp":1536106913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480016303112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0014480016303112"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2017.01.006","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}